Searching for Synergy: Chemotherapy and Checkpoint Inhibitors
Diane Tseng1, Justin F Gainor2,3
1Fred Hutchinson Cancer Center, Seattle, Washington.
Abstract:
Continuation of programmed cell death protein 1 (PD-1) inhibitors in combination with chemotherapy did not improve clinical outcomes for patients with non-small cell lung cancer who progressed on prior PD-1/programmed death ligand 1 inhibitor monotherapy. This highlights the need to evaluate the precise mechanisms of resistance to PD-1 axis inhibitors and explore alternative therapeutic strategies to overcome resistance. See related article by Jung et al., p. 2321.
Insights
Adding chemotherapy to PD-1 inhibitors did not improve outcomes for lung cancer patients previously treated with PD-1/PD-L1 inhibitors. Further research is needed to understand resistance and find new therapies.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Programmed cell death protein 1 (PD-1) inhibitors are a cornerstone of non-small cell lung cancer (NSCLC) treatment.
- Prior studies have shown efficacy of PD-1 inhibitors in advanced NSCLC.
- Resistance to PD-1 axis inhibitors is a significant clinical challenge.
Discussion:
- This study investigated the efficacy of continuing PD-1 inhibitors in combination with chemotherapy for NSCLC patients who progressed on prior PD-1/PD-L1 inhibitor monotherapy.
- The combination strategy did not demonstrate improved clinical outcomes compared to standard care.
- This suggests that sequential or combination approaches may not overcome established resistance mechanisms.
Key Insights:
- Continuation of PD-1 inhibitors with chemotherapy offers no benefit in NSCLC patients resistant to prior PD-1/PD-L1 therapy.
- Mechanisms of resistance to PD-1 axis inhibitors require further elucidation.
- Alternative therapeutic strategies are essential to overcome treatment resistance.
Outlook:
- Future research should focus on identifying predictive biomarkers for PD-1 resistance.
- Exploring novel therapeutic combinations targeting alternative immune checkpoints or pathways is crucial.
- Developing strategies to re-sensitize tumors to immunotherapy is a key area for future investigation.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:27Tumor Immunotherapy
699
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
699
01:27Combined Effects of Drugs: Synergism
5.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
5.0K
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
276
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
276
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K